Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 59
Filter
1.
BMJ Open Respir Res ; 11(1)2024 02 29.
Article in English | MEDLINE | ID: mdl-38423954

ABSTRACT

INTRODUCTION: Lung volume reduction surgery (LVRS) and endobronchial valve (EBV) placement can produce substantial benefits in appropriately selected people with emphysema. The UK Lung Volume Reduction (UKLVR) registry is a national multicentre observational study set up to support quality standards and assess outcomes from LVR procedures at specialist centres across the UK. METHODS: Data were analysed for all patients undergoing an LVR procedure (LVRS/EBV) who were recruited into the study at participating centres between January 2017 and June 2022, including; disease severity and risk assessment, compliance with guidelines for selection, procedural complications and survival to February 2023. RESULTS: Data on 541 patients from 14 participating centres were analysed. Baseline disease severity was similar in patients who had surgery n=244 (44.9%), or EBV placement n=219 (40.9%), for example, forced expiratory volume in 1 s (FEV1) 32.1 (12.1)% vs 31.2 (11.6)%. 89% of cases had discussion at a multidisciplinary meeting recorded. Median (IQR) length of stay postprocedure for LVRS and EBVs was 12 (13) vs 4 (4) days(p=0.01). Increasing age, male gender and lower FEV1%predicted were associated with mortality risk, but survival did not differ between the two procedures, with 50 (10.8%) deaths during follow-up in the LVRS group vs 45 (9.7%) following EBVs (adjusted HR 1.10 (95% CI 0.72 to 1.67) p=0.661) CONCLUSION: Based on data entered in the UKLVR registry, LVRS and EBV procedures for emphysema are being performed in people with similar disease severity and long-term survival is similar in both groups.


Subject(s)
Emphysema , Pulmonary Emphysema , Humans , Male , Lung/surgery , Pneumonectomy/adverse effects , Pneumonectomy/methods , Pulmonary Emphysema/surgery , Registries , United Kingdom , Female
2.
J Med Chem ; 66(3): 1941-1954, 2023 02 09.
Article in English | MEDLINE | ID: mdl-36719971

ABSTRACT

Long-acting (LA) human immunodeficiency virus-1 (HIV-1) antiretroviral therapy characterized by a ≥1 month dosing interval offers significant advantages over daily oral therapy. However, the criteria for compounds that enter clinical development are high. Exceptional potency and low plasma clearance are required to meet dose size requirements; excellent chemical stability and/or crystalline form stability is required to meet formulation requirements, and new antivirals in HIV-1 therapy need to be largely free of side effects and drug-drug interactions. In view of these challenges, the discovery that capsid inhibitors comprising a quinazolinone core tolerate a wide range of structural modifications while maintaining picomolar potency against HIV-1 infection in vitro, are assembled efficiently in a multi-component reaction, and can be isolated in a stereochemically pure form is reported herein. The detailed characterization of a prototypical compound, GSK878, is presented, including an X-ray co-crystal structure and subcutaneous and intramuscular pharmacokinetic data in rats and dogs.


Subject(s)
Anti-HIV Agents , HIV Infections , HIV-1 , Humans , Rats , Animals , Dogs , Capsid , Capsid Proteins , Quinazolinones/pharmacology , Quinazolinones/therapeutic use , Anti-HIV Agents/pharmacokinetics , HIV Infections/drug therapy
3.
ACS Med Chem Lett ; 13(6): 972-980, 2022 Jun 09.
Article in English | MEDLINE | ID: mdl-35707159

ABSTRACT

Allosteric HIV-1 integrase inhibitors (ALLINIs) have been of interest recently because of their novel mechanism of action. Strategic modifications to the C5 moiety of a class of 4-(4,4-dimethylpiperidinyl)-2,6-dimethylpyridinyl ALLINIs led to the identification of a tetrahydroisoquinoline heterocycle as a suitable spacer element to project the distal hydrophobic aryl ring. Subsequent optimization of the aryl substitutions identified 12 as an ALLINI with single-digit nanomolar inhibitory potency and low clearance across preclinical species. In preclinical toxicology studies with 12 in rats, lipid hepatocellular vacuolation was observed. Removal of the C6 methyl group resulted in GSK3839919 (22), which exhibited a reduced incidence and severity of lipid vacuolation in both in vitro assays and in vivo studies while maintaining the potency and pharmacokinetic (PK) properties of the prototype. The virology, PK, and toxicology profiles of 22 are discussed.

4.
Bioorg Med Chem ; 67: 116833, 2022 08 01.
Article in English | MEDLINE | ID: mdl-35605346

ABSTRACT

Allosteric integrase inhibitors (ALLINIs) of HIV-1 may hold promise as a novel mechanism for HIV therapeutics and cure. Scaffold modifications to the 4-(4,4-dimethylpiperidinyl) 2,6-dimethylpyridinyl class of ALLINIs provided a series of potent compounds with differentiated 5/6 fused ring systems. Notably, inhibitors containing the 1,2,4-triazolopyridine and imidazopyridine core exhibited single digit nM antiviral potency and low to moderate clearance after intravenous (IV) dosing in rat pharmacokinetic (PK) studies. The 1,2,4-triazolopyridines showed a higher oral exposure when compared to the imidazopyridines. Further modifications to the C5 substituent of the 1,2,4-triazolopyridines resulted in a new lead compound, which had improved rat IV/PO PK compared to the former lead compound GSK3739936, while maintaining antiviral potency. Structure-activity relationships (SAR) and rat pharmacokinetic profiles of this series are discussed.


Subject(s)
Anti-HIV Agents , HIV Integrase Inhibitors , HIV Integrase , HIV-1 , Allosteric Regulation , Animals , Anti-HIV Agents/pharmacology , HIV Integrase/metabolism , HIV Integrase Inhibitors/pharmacology , HIV-1/metabolism , Rats
5.
J Med Chem ; 65(6): 4949-4971, 2022 03 24.
Article in English | MEDLINE | ID: mdl-35235334

ABSTRACT

Allosteric HIV-1 integrase inhibitors (ALLINIs) have garnered special interest because of their novel mechanism of action: they inhibit HIV-1 replication by promoting aberrant integrase multimerization, leading to the production of replication-deficient viral particles. The binding site of ALLINIs is in a well-defined pocket formed at the interface of two integrase monomers that is characterized by conserved residues along with two polymorphic amino acids at residues 124 and 125. The design, synthesis, and optimization of pyridine-based allosteric integrase inhibitors are reported here. Optimization was conducted with a specific emphasis on the inhibition of the 124/125 polymorphs such that the designed compounds showed excellent potency in vitro against majority of the 124/125 variants. In vivo profiling of promising preclinical lead 29 showed that it exhibited a good pharmacokinetic (PK) profile in preclinical species, which resulted in a low predicted human efficacious dose. However, findings in rat toxicology studies precluded further development of 29.


Subject(s)
HIV Integrase Inhibitors , HIV Integrase , HIV-1 , Allosteric Regulation , Animals , HIV Integrase/metabolism , HIV Integrase Inhibitors/chemistry , HIV Integrase Inhibitors/pharmacology , HIV-1/physiology , Rats
6.
Biol Trace Elem Res ; 200(4): 1485-1494, 2022 Apr.
Article in English | MEDLINE | ID: mdl-34076844

ABSTRACT

A total of 158 serum samples of newly diagnosed type 2 diabetes patients and control subjects were analyzed using Synchrotron Radiation X-ray Fluorescence (SRXRF) technique. The microprobe XRF beam line-16 of Indus-2 synchrotron radiation facility at Raja Ramanna Centre for Advanced Technology (RRCAT), Indore, India, was used to identify and quantify the elements K, Ca, Ti, V, Cr, Mn, Fe, Co, Ni, Cu, Zn, As, Se, Br, Rb, Sr, and Pb. A significant decrease in the mean concentrations of K, Ca, Ti, Cr, Mn, Ni, Zn, and As and an increase in the concentrations of V, Fe, Co, Cu, Se, and Pb were observed in the serum samples of the patient group when compared to the control group. It is hypothesized that the observed alterations in the elemental concentrations might have led to ineffective uptake of insulin and have interfered with glucose homeostasis by either directly or indirectly causing oxidative stress.


Subject(s)
Diabetes Mellitus, Type 2 , Trace Elements , Fluorescence , Humans , India , Synchrotrons , Trace Elements/analysis , X-Rays
7.
Bioorg Med Chem Lett ; 30(22): 127531, 2020 11 15.
Article in English | MEDLINE | ID: mdl-32890685

ABSTRACT

Previous studies have identified a series of imidazo[1,2-a]pyridine (IZP) derivatives as potent allosteric inhibitors of HIV-1 integrase (ALLINIs) and virus infection in cell culture. However, IZPs were also found to be relatively potent activators of the pregnane-X receptor (PXR), raising the specter of induction of CYP-mediated drug disposition pathways. In an attempt to modify PXR activity without affecting anti-HIV-1 activity, rational structure-based design and modeling approaches were used. An X-ray cocrystal structure of (S,S)-1 in the PXR ligand binding domain (LBD) allowed an examination of the potential of rational structural modifications designed to abrogate PXR. The introduction of bulky basic amines at the C-8 position provided macrocyclic IZP derivatives that displayed potent HIV-1 inhibitory activity in cell culture with no detectable PXR transactivation at the highest concentration tested.


Subject(s)
Anti-HIV Agents/pharmacology , HIV Integrase Inhibitors/pharmacology , HIV-1/drug effects , Macrocyclic Compounds/pharmacology , Pregnane X Receptor/antagonists & inhibitors , Allosteric Regulation/drug effects , Anti-HIV Agents/chemical synthesis , Anti-HIV Agents/chemistry , Cells, Cultured , Dose-Response Relationship, Drug , HIV Integrase Inhibitors/chemical synthesis , HIV Integrase Inhibitors/chemistry , Humans , Macrocyclic Compounds/chemical synthesis , Macrocyclic Compounds/chemistry , Microbial Sensitivity Tests , Molecular Structure , Pregnane X Receptor/metabolism , Structure-Activity Relationship , Virus Replication/drug effects
8.
Bioorg Med Chem Lett ; 30(21): 127516, 2020 11 01.
Article in English | MEDLINE | ID: mdl-32860982

ABSTRACT

The design, synthesis and structure-activity relationships associated with a series of C2-substituted pyrazolopyrimidines as potent allosteric inhibitors of HIV-1 integrase (ALLINIs) are described. Structural modifications to these molecules were made in order to examine the effect on potency and, for select compounds, pharmacokinetic properties. We examined a variety of C2-substituted pyrazolopyrimidines and found that the C2-amide derivatives demonstrated the most potent antiviral activity of this class against HIV-1 infection in cell culture.


Subject(s)
Amides/pharmacology , Anti-HIV Agents/pharmacology , HIV Integrase Inhibitors/pharmacology , HIV Integrase/metabolism , Pyrazoles/pharmacology , Pyrimidines/pharmacology , Allosteric Regulation/drug effects , Amides/chemical synthesis , Amides/chemistry , Anti-HIV Agents/chemical synthesis , Anti-HIV Agents/chemistry , Cells, Cultured , Dose-Response Relationship, Drug , Drug Design , HIV Integrase Inhibitors/chemical synthesis , HIV Integrase Inhibitors/chemistry , HIV-1/drug effects , HIV-1/metabolism , Humans , Microbial Sensitivity Tests , Molecular Structure , Pyrazoles/chemical synthesis , Pyrazoles/chemistry , Pyrimidines/chemical synthesis , Pyrimidines/chemistry , Structure-Activity Relationship
9.
Bioorg Med Chem ; 28(13): 115541, 2020 07 01.
Article in English | MEDLINE | ID: mdl-32389483

ABSTRACT

The design, synthesis and structure-activity relationships associated with a series of bridged tricyclic pyrimidinone carboxamides as potent inhibitors of HIV-1 integrase strand transfer are described. Structural modifications to these molecules were made in order to examine the effect on potency towards wild-type and clinically-relevant resistant viruses. The [3.2.2]-bridged tricyclic system was identified as an advantageous chemotype, with representatives exhibiting excellent antiviral activity against both wild-type viruses and the G140S/Q148H resistant virus that arises in response to therapy with raltegravir and elvitegravir.


Subject(s)
Antiviral Agents/chemical synthesis , HIV Infections/drug therapy , HIV Integrase Inhibitors/chemical synthesis , HIV Integrase/metabolism , Imidazoles/chemical synthesis , Pyrrolidinones/chemistry , Antiviral Agents/pharmacology , Drug Resistance, Viral/drug effects , Drug Therapy, Combination , HIV Integrase Inhibitors/pharmacology , HIV-1/drug effects , Humans , Imidazoles/pharmacology , Mutation , Quinolones/pharmacology , Raltegravir Potassium/pharmacology , Structure-Activity Relationship
10.
J Med Chem ; 63(5): 2620-2637, 2020 03 12.
Article in English | MEDLINE | ID: mdl-32081010

ABSTRACT

The standard of care for HIV-1 infection, highly active antiretroviral therapy (HAART), combines two or more drugs from at least two classes. Even with the success of HAART, new drugs with novel mechanisms are needed to combat viral resistance, improve adherence, and mitigate toxicities. Active site inhibitors of HIV-1 integrase are clinically validated for the treatment of HIV-1 infection. Here we describe allosteric inhibitors of HIV-1 integrase that bind to the LEDGF/p75 interaction site and disrupt the structure of the integrase multimer that is required for the HIV-1 maturation. A series of pyrazolopyrimidine-based inhibitors was developed with a vector in the 2-position that was optimized by structure-guided compound design. This resulted in the discovery of pyrazolopyrimidine 3, which was optimized at the 2- and 7-positions to afford 26 and 29 as potent allosteric inhibitors of HIV-1 integrase that exhibited low nanomolar antiviral potency in cell culture and encouraging PK properties.


Subject(s)
Allosteric Regulation/drug effects , HIV Integrase Inhibitors/chemistry , HIV Integrase Inhibitors/pharmacology , HIV-1/drug effects , Pyrazoles/chemistry , Pyrazoles/pharmacology , Pyridines/chemistry , Pyridines/pharmacology , Administration, Oral , Animals , Drug Discovery , HIV Infections/drug therapy , HIV Infections/virology , HIV Integrase/metabolism , HIV Integrase Inhibitors/administration & dosage , HIV Integrase Inhibitors/pharmacokinetics , Humans , Male , Molecular Docking Simulation , Pyrazoles/administration & dosage , Pyrazoles/pharmacokinetics , Pyridines/administration & dosage , Pyridines/pharmacokinetics , Rats, Sprague-Dawley
11.
Physiotherapy ; 106: 87-93, 2020 03.
Article in English | MEDLINE | ID: mdl-31000366

ABSTRACT

OBJECTIVES: Following major thoracic surgery physiotherapy is recommended to improve reduced lung volume, aid secretion clearance, and improve mobility, however, in many centres physiotherapy provision is variable following minimally invasive video-assisted thoracoscopic surgery (VATS). The objective of this study was to observe frequency of problems potentially amenable to physiotherapy following VATS lobectomy, and to identify associated baseline factors of patients in whom physiotherapy may be beneficial. METHODS: A prospective observational study was performed including all consecutive cancer patients undergoing VATS lobectomy in a regional centre over 4years (2012-2016). Standard postoperative care included early mobilisation by nursing staff from postoperative day one (POD1). Physiotherapy assessment of all patients on POD1 determined presence of issues potentially amenable to physiotherapy intervention, and treatment was commenced. Outcome measures included postoperative pulmonary complication (PPC) development, hospital and high dependency unit (HDU) length of stay (LOS). RESULTS: Of 285 patients, 209 (73%) received physiotherapy to assist/improve reduced mobility, of these 23 (8%) also received sputum clearance therapies and 65 (23%) specific therapy for lung volume loss. The remaining 76 (27%) patients had significantly lower hospital/HDU LOS (P<0.001) reflecting uncomplicated recovery. Chronic obstructive pulmonary disease (COPD), body mass index (BMI), preoperative mobility and age were independently associated with issues potentially amenable to physiotherapy (P=0.013). CONCLUSION: Following VATS lobectomy a large proportion of patients demonstrated issues potentially amenable to physiotherapy. The authors recommend that patients receive routine physiotherapy assessment following this type of surgery to ensure that all issues are identified early. Screening of COPD, BMI, preoperative mobility and age will allow early identification of patients who may benefit most from postoperative physiotherapy and preoperative optimisation, however, these factors cannot predict the need for physiotherapy.


Subject(s)
Patient Selection , Physical Therapy Modalities , Thoracic Surgery, Video-Assisted , Aged , Aged, 80 and over , Female , Humans , Length of Stay , Lung/surgery , Male , Middle Aged , Postoperative Care , Postoperative Complications/prevention & control , Prospective Studies , Risk Factors
12.
Bioorg Med Chem Lett ; 30(3): 126784, 2020 02 01.
Article in English | MEDLINE | ID: mdl-31761656

ABSTRACT

A series of heterocyclic pyrimidinedione-based HIV-1 integrase inhibitors was prepared and screened for activity against purified integrase enzyme and/or viruses modified with the following mutations within integrase: Q148R, Q148H/G140S and N155H. These are mutations that result in resistance to the first generation integrase inhibitors raltegravir and elvitegravir. Based on consideration of drug-target interactions, an approach was undertaken to replace the amide moiety of the first generation pyrimidinedione inhibitor with azole heterocycles that could retain potency against these key resistance mutations. An imidazole moiety was found to be the optimal amide substitute and the observed activity was rationalized with the use of calculated properties and modeling. Rat pharmacokinetic (PK) studies of the lead imidazole compounds demonstrated moderate clearance and moderate exposure.


Subject(s)
Amides/chemistry , HIV Integrase Inhibitors/chemistry , HIV Integrase/chemistry , HIV-1/enzymology , Heterocyclic Compounds, 3-Ring/chemistry , Animals , Binding Sites , Catalytic Domain , Drug Resistance, Viral/drug effects , HIV Integrase/genetics , HIV Integrase/metabolism , HIV Integrase Inhibitors/metabolism , HIV Integrase Inhibitors/pharmacology , HIV-1/drug effects , Half-Life , Heterocyclic Compounds, 3-Ring/metabolism , Heterocyclic Compounds, 3-Ring/pharmacology , Humans , Molecular Dynamics Simulation , Mutation , Rats , Structure-Activity Relationship
13.
J Toxicol ; 2019: 3042108, 2019.
Article in English | MEDLINE | ID: mdl-31781202

ABSTRACT

A 90-day repeated-dose oral toxicological evaluation was conducted according to GLP and OECD guidelines on lyophilized spores of the novel genetically modified strain B. subtilis ZB183. Lyophilized spores at doses of 109, 1010, and 1011 CFU/kg body weight/day were administered by oral gavage to Wistar rats for a period of 90 consecutive days. B. subtilis ZB183 had no effects on clinical signs, mortality, ophthalmological examinations, functional observational battery, body weights, body weight gains and food consumption in both sexes. There were no test item-related changes observed in haematology, coagulation, urinalysis, thyroid hormonal analysis, terminal fasting body weights, organ weights, gross pathology and histopathology. A minimal increase in the plasma albumin level was observed at 1010 and 1011 CFU/kg/day doses without an increase in total protein in males or females and was considered a nonadverse effect. The "No Observed Adverse Effect Level (NOAEL)" is defined at the highest dose of 1011 CFU/kg body weight/day for lyophilized B. subtilis ZB183 Spores under the test conditions employed.

14.
J Med Chem ; 62(3): 1348-1361, 2019 02 14.
Article in English | MEDLINE | ID: mdl-30609350

ABSTRACT

A series of 5,6,7,8-tetrahydro-1,6-naphthyridine derivatives targeting the allosteric lens-epithelium-derived-growth-factor-p75 (LEDGF/p75)-binding site on HIV-1 integrase, an attractive target for antiviral chemotherapy, was prepared and screened for activity against HIV-1 infection in cell culture. Small molecules that bind within the LEDGF/p75-binding site promote aberrant multimerization of the integrase enzyme and are of significant interest as HIV-1-replication inhibitors. Structure-activity-relationship studies and rat pharmacokinetic studies of lead compounds are presented.


Subject(s)
HIV Integrase Inhibitors/pharmacology , HIV-1/drug effects , Naphthyridines/pharmacology , Allosteric Site , Crystallography, X-Ray , HIV Infections/drug therapy , HIV Integrase Inhibitors/chemistry , HIV Integrase Inhibitors/therapeutic use , HIV-1/enzymology , HIV-1/physiology , Humans , Naphthyridines/chemistry , Naphthyridines/therapeutic use , Virus Replication/drug effects
15.
Bioorg Med Chem Lett ; 28(12): 2124-2130, 2018 07 01.
Article in English | MEDLINE | ID: mdl-29779976

ABSTRACT

BMS-707035 is an HIV-1 integrase strand transfer inhibitor (INSTI) discovered by systematic optimization of N-methylpyrimidinone carboxamides guided by structure-activity relationships (SARs) and the single crystal X-ray structure of compound 10. It was rationalized that the unexpectedly advantageous profiles of N-methylpyrimidinone carboxamides with a saturated C2-substitutent may be due, in part, to the geometric relationship between the C2-substituent and the pyrimidinone core. The single crystal X-ray structure of 10 provided support for this reasoning and guided the design of a spirocyclic series 12 which led to discovery of the morpholino-fused pyrimidinone series 13. Several carboxamides derived from this bicyclic scaffold displayed improved antiviral activity and pharmacokinetic profiles when compared with corresponding spirocyclic analogs. Based on the excellent antiviral activity, preclinical profiles and acceptable in vitro and in vivo toxicity profiles, 13a (BMS-707035) was selected for advancement into phase I clinical trials.


Subject(s)
Anti-HIV Agents/pharmacology , Drug Discovery , HIV Integrase Inhibitors/pharmacology , HIV Integrase/metabolism , HIV/drug effects , Pyrimidines/pharmacology , Pyrimidinones/pharmacology , Thiazines/pharmacology , Anti-HIV Agents/chemical synthesis , Anti-HIV Agents/chemistry , Dose-Response Relationship, Drug , HIV Integrase Inhibitors/chemical synthesis , HIV Integrase Inhibitors/chemistry , Humans , Microbial Sensitivity Tests , Molecular Structure , Pyrimidines/chemical synthesis , Pyrimidines/chemistry , Pyrimidinones/chemical synthesis , Pyrimidinones/chemistry , Structure-Activity Relationship , Thiazines/chemical synthesis , Thiazines/chemistry
16.
J Oral Maxillofac Pathol ; 22(3): 446, 2018.
Article in English | MEDLINE | ID: mdl-30651703

ABSTRACT

BACKGROUND: Ameloblastoma (AM) is a benign odontogenic neoplasm characterized by local invasiveness and recurrence. We have evaluated the immunohistochemical expressions of osteonectin (ON), matrix metalloproteinase-9 (MMP-9) and Ki-67 in AM to understand the biologic behavior of this neoplasm. AIM: The aim of this study is to evaluate the expression of ON, MMP-9 and Ki-67 in AM. MATERIALS AND METHODS: The study sample included archival tissues embedded in paraffin blocks histopathologically diagnosed as AM (20 cases). Three serial sections of each tissue specimen were stained separately with ON, MMP-9 and Ki-67 (immunohistochemistry stain) and evaluated. The data were analyzed using Spearman rank correlation test. RESULTS: All AM cases 20/20 (100%) exhibited positive immunostaining for ON, MMP-9 and Ki-67. CONCLUSION: Increased expression of ON, MMP-9 and Ki-67 in AM indicates that these molecules might play a role in the regulation and aggressive nature of this neoplasm.

18.
Article in English | MEDLINE | ID: mdl-27965826

ABSTRACT

BACKGROUND: Stage I non-small cell lung cancer (NSCLC) is potentially curable, and surgery is considered to be the standard of care for patients with good performance status and minimal co-morbidity. However, a significant proportion of patients with stage I NSCLC have a poorer performance status and significant medical co-morbidity that make them at higher risk of morbidity and mortality from surgery. Stereotactic ablative radiotherapy (SABR), which uses modern radiotherapeutic techniques to deliver large doses of radiation, has shown superiority over conventional radiotherapy in terms of local control and toxicity and is a standard of care for patients with stage I NSCLC who are at too high risk for surgery. However, it is not known whether surgery or SABR is the most effective in patients with stage I NSCLC who are suitable for surgery but are less fit and at higher risk surgical complications. Previous randomised studies have failed to recruit in this setting, and therefore, a feasibility study is required to see whether a full randomised control trial would be possible. METHODS/DESIGN: SABRTooth is a UK-based, multi-centre, open-label, two-group individually (1:1) randomised controlled feasibility study in patients with peripheral stage I NSCLC considered to be at higher risk from surgical resection. The study will assess the feasibility of conducting a definitive large-scale phase III trial. The primary objective is to assess recruitment rates to provide evidence that, when scaled up, recruitment to a large phase III trial would be possible; the target recruitment being 54 patients in total, over a 21-month period. There are multiple secondary and exploratory objectives designed to explore the optimum recruitment and data collection strategies to help optimise the design of a future phase III trial. DISCUSSION: To know whether SABR is a better, equivalent or inferior alternative to surgery for higher risk patients is a key question in lung cancer. Other studies comparing SABR to surgery have closed early due to poor recruitment, and therefore, the SABRTooth feasibility study has been designed around the UK National Health Service (NHS) cancer pathway incorporating many design features in order to maximise recruitment for a future definitive phase III trial. TRIAL REGISTRATION: controlled-trials.com ISRCTN13029788.

19.
Ann Med Health Sci Res ; 6(2): 80-4, 2016.
Article in English | MEDLINE | ID: mdl-27213089

ABSTRACT

BACKGROUND: Dental caries is the most common infectious disease affecting humans and is the predominant cause of tooth loss in children. Although Candida's role in dental caries has been studied extensively, limited homogenous studies have been conducted and none have been found, that associate Candida with dental caries, while correlating it to different age groups. AIM: The study aimed to quantify oral Candida in school children and correlate candidal carriage to the caries index and further analyze an age association. SUBJECTS AND METHODS: Decayed-Filled teeth/Decayed-Missing-Filled Teeth (dft/DMFT) index scores of 150 subjects were evaluated, and concentrated oral rinse samples were collected from each participant for mycologic investigation. Based on the age and caries activity, the participants were categorized into three groups consisting of 50 each such as Group-I (caries active participants of 6-12 years age), Group-II (caries active participants in 13-18 years age), and Group-III (caries-free participants in 6-18 years age); CHROMagar™ was used as a primary culture medium for candidal growth. The data was statistically analyzed using Unpaired t-test, Chi-square test and Spearman's rank order. RESULTS: The results demonstrated that as age increases, the dft/DMFT scores as well as the candidal growth decreased. In addition, the oral candidal carriage levels were found to be low in caries-free group (Group-III) when compared to the study groups. CONCLUSION: The presence of Candida was directly related to the caries status and inversely proportional to the age.

20.
Tumour Biol ; 37(8): 10357-64, 2016 Aug.
Article in English | MEDLINE | ID: mdl-26846100

ABSTRACT

Mitochondrial displacement loop (D-loop) is a hot spot for mitochondrial DNA (mtDNA) alterations that effects cellular reactive oxygen species (ROS) generation. Manganese-superoxide dismutase (Mn-SOD) is a major antioxidant enzyme that protects cells from ROS-mediated damage. In the present study, we investigated the relationship between sequence alterations of mitochondrial D-loop and Mn-SOD expression in colorectal cancer (CRC). Genotyping of entire mitochondrial D-loop (1124 bp) was carried out on mtDNA of analogous tumor and normal tissues from 35 CRC patients of south Indian origin by PCR-sequencing analysis. Tumor-specific large-scale mtDNA deletions and Mn-SOD expression was analyzed by PCR and Western blot analysis, respectively. We identified 87 polymorphisms in the D-loop region of tumor and/or control tissues. Polymorphisms were predominantly located in hypervariable region I (67.9 %) than in II (32.1 %) of D-loop. Significantly increased mtDNA microsatellite instability (mtMSI) [310'C' insertion (P = 0.00001) and T16189C (P = 0.0007)] and elevated Mn-SOD expression was observed in tumor tissues compared with controls. Interestingly, mtMSI was significantly high in tumors with Mn-SOD overexpression. Tumor-specific large-scale mtDNA deletions were not observed in CRC tissues. In conclusion, mtMSI and Mn-SOD overexpression are a common event in CRC. The analysis of mtMSI and/or Mn-SOD expression might help to identify patients at high risk for disease outcome, thereby helping to refine therapeutic decisions in CRC.


Subject(s)
Adenocarcinoma/enzymology , Adenocarcinoma/genetics , Colorectal Neoplasms/enzymology , Colorectal Neoplasms/genetics , DNA, Mitochondrial/genetics , Superoxide Dismutase/biosynthesis , Adenocarcinoma/pathology , Adult , Aged , Blotting, Western , Colorectal Neoplasms/pathology , Female , Genotype , Humans , Male , Microsatellite Instability , Middle Aged , Polymerase Chain Reaction
SELECTION OF CITATIONS
SEARCH DETAIL
...